Development and performance of the zotarolimus-eluting Endeavor® coronary stent

Expert Review of Medical Devices

Volumn 7, Issue 4, 2010, Pages 449-459

  Kandzari, David E ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Drug eluting stents; Percutaneous coronary intervention; Stent thrombosis; Zotarolimus

Indexed keywords

ACETYLSALICYLIC ACID; PACLITAXEL; PHOSPHORYLCHOLINE; POLYMER; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; ZOTAROLIMUS; ANTITHROMBOCYTIC AGENT;

ACUTE HEART INFARCTION; BARE METAL STENT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DEVICE SAFETY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ENDOTHELIUM; HEART DEATH; HUMAN; INTRAVASCULAR ULTRASOUND; NEOINTIMA; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; STENT THROMBOSIS; VASODILATATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HEART; STANDARDS;

CLINICAL TRIALS AS TOPIC; DRUG-ELUTING STENTS; HEART; HUMANS; PLATELET AGGREGATION INHIBITORS; SIROLIMUS;

EID: 77954226059     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.10.31     Document Type: Review

References (67)

1. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331(8), 496-501 (1994).
2. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14), 1315-1323 (2003).
3. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350(3), 221-2231 (2004).
4. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al.; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J. Am. Coll. Cardiol. 47(1), e1-e121 (2006).
5. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364(9444), 1519-1521 (2004). (Pubitemid 39410418)
6. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115(11), 1440-1445 (2007).
7. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356(10), 998-1008 (2007).
8. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109, 701-705 (2004).
9. Finn AV, Kolodgie FD, Harnek J et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112(2), 270-278 (2005).
10. Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol. 47(1), 175-181 (2006).
11. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48(1), 193-202 (2006).
12. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126-2130 (2005).
13. Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am. J. Cardiol. 98(3), 352-356 (2006).
14. Slottow TLP, Waksman R. Drug-eluting stent safety. Am. J. Cardiol. 100(8 Suppl. 2), S10-S17 (2007).
15. Mauri L, Hsieh WH, Massaro JM, Ho KKL, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 356(10), 1020-1029 (2007).
16. Grines CL, Bonow RO, Casey DE Jr et al.; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental. Circulation 115(6), 813-818 (2007).
17. Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ; Driver Investigators. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am. J. Cardiol. 95(1), 8-12 (2005).
18. Ako J, Bonneau HN, Honda Y, Fitzgerald PJ. Design criteria for the ideal drug-eluting stent. Am. J. Cardiol. 100(8B), 3M-9M (2007).
19. Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103(23), 2816-2821 (2001).
20. Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol. 52(5), 333-342 (2008).
21. Zahedmanesh H, Lally C. Determination of the influence of stent strut thickness using the finite element method: implications for vascular injury and in-stent restenosis. Med. Biol. Eng. Comput. 47(4), 385-393 (2009).
22. Collingwood R, Gibson L, Sedlik S, Virmani R, Carter AJ. Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model. Catheter. Cardiovasc. Interv. 65(2), 227-232 (2005).
23. Commandeur S, van Beusekom HM, van der Giessen WJ. Polymers, drug release, and drug-eluting stents. J. Interv. Cardiol. 19(6), 500-506 (2006).
24. Lewis AL, Furze JD, Small S et al. Long-term stability of a coronary stent coating post-implantation. J. Biomed. Mater. Res. 63(6), 699-705 (2002).
25. Boland JL, Corbeij HA, Van Der Giessen W et al. Multicenter evaluation of the phosphorylcholine-coated biodivYsio stent in short de novo coronary lesions: the SOPHOS study. Int. J. Cardiovasc. Intervent. 3(4), 215-225 (2000).
26. Burke SE, Kuntz RE, Schwartz LB. Zotarolomus (ABT-578) eluting stents. Adv. Drug Deliv. Rev. 58(3), 437-446 (2006).
27. Garcia-Touchard A, Burke SE, Toner JL, Cromack K, Schwartz RS. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur. Heart J. 27(8), 988-993 (2006).
28. Chevalier B, Di Mario C, Neumann FJ et al.; ZoMaxx I Investigators. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: the ZoMaxx I trial. JACC Cardiovasc. Interv. 1(5), 524-532 (2008).
29. Meredith IT, Worthley S, Whitbourn R et al. Clinical and angiographic results with the next-generation Resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc. Interv. 2(10), 977-985 (2009).
30. Meredith IT, Ormiston J, Whitbourn R et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 1, 157-164 (2005).
31. Fajadet J, Wijns W, Laarman GJJ et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the Endeavor II trial. Circulation 114(8), 798-806 (2006).
32. Schultheiss HP, Grube E, Kuck KH et al. Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry. EuroIntervention 3, 76-81 (2007).
33. Kandzari DE, Leon MB, Popma JJ et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol. 48(12), 2440-2447 (2006).
34. Abbott Laboratories. Pharmacokinetics of ABT-578 in patients from Endeavor Stent: results from a subset of a double-blind, randomized, multicenter (ENDEAVOR-II) Trial. The ENDEAVOR II study 30-day pharmacokinetic report - internal Medtronic report. July 6 (2004).
35. Leon MB, Mauri L, Popma JJ et al.; ENDEAVOR IV Investigators. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the Taxus paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV Trial. J. Am. Coll. Cardiol. 55, 543-554 (2010).
36. Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT; E-Five Investigators. Safety and efficacy of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five Registry. J. Am. Coll. Cardiol. Interv. 2(12), 1227-1235 (2009).
37. Wijns W, Fajadet J, Laarman GJ et al. Randomised trial comparing the ENDEAVOR zotarolimus-eluting stent and the Driver bare-metal stent in single de novo native coronary artery lesions: five-year clinical follow-up of ENDEAVOR II [abstract]. EuroIntervention 5(Suppl. E), E27 (2009).
38. Kandzari DE, Mauri L, Popma JJ et al. Five year clinical results from ENDEAVOR III: a randomized comparison of the zotarolimus-eluting versus sirolimus-eluting stents in de novo native coronary lesions [abs]. J. Am. Coll. Cardiol. 55(10), A193 (2010).
39. Leon MB, Mauri L, O'Shaughnessy C et al. Late safety and efficacy of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: three-year follow-up from the ENDEAVOR IV trial [abstract TCT-404]. Am. J. Cardiol. 104(6), 150D (2009).
40. Kandzari D, Leon MB, Mauri L et al. Long term efficacy outcomes following treatment with zotarolimus-eluting stents: analysis of the pooled Endeavor programme [abstract]. EuroIntervention 5(Suppl. E), E28 (2009).
41. Mauri L. Long term safety results from the Endeavor Program: five-year follow-up. Presented at: The Official Congress of the European Association of Percutaneous Cardiovascular Interventions. Barcelona, Spain, 19-22 May 2009.
42. Meredith IT. Real world outcomes in patients with coronary artery disease treated with the Endeavor ZES: 2-year results from the E-Five Registry. Presented at: the official congress of the European Association of Percutaneous Cardiovascular Interventions. Barcelona, Spain, 19-22 May 2009.
43. Park SJ. ZEST Trial: comparison of the effiacy and safety of zotarolimus-eluting stent versus zirolimus-eluting stent and paclitaxel-eluting stent for coronary lesions. Presented at: American College of Cardiology Scientific Sessions. Orlando, FL, USA, 29 March 2009.
44. Lee CW, Kim YH, Park SJ. Final angiographic and IVUS results from the ZEST trial. Presented at: Transcatheter Therapeutics (TCT) Scientific Sessions. San Francisco, CA, USA, 24 September 2009.
45. Park SJ. ZEST-AMI: a prospective randomized comparison of zotarolimus-eluting Stents, sirolimus-eluting stents, and paclitaxel-eluting stents in patients with acute myocardial infarction. Presented at: Transcatheter Therapeutics (TCT) Scientific Sessions. Washington, DC, USA, 12 October 2008.
46. Rasmussen K, Maeng M, Kaltoft A et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomized controlled superiority trial. Lancet 375(9720), 1090-1099 (2010).
47. Miyazawa A, Ako J, Hongo Y et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from Endeavor III. Am. Heart J. 155(1), 108-113 (2008).
48. Waseda K, Miyazawa A, Ako J et al. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. J. Am. Coll. Cardiol. Intv. 22(8), 779-784 (2009).
49. Sakurai R, Bonneau HN, Honda Y, Fitzgerald PJ. Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. Am. J. Cardiol. 100, 71M-76M (2007).
50. Cook S, Wenaweser P, Togni M et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115(18), 2426-2434 (2007).
51. Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120(4) 391-399 (2009).
52. Guagliumi G. ODESSA: a prospective randomized study using optical coherence tomography to evaluate strut coverage of sirolimus-eluting, paclitaxel-eluting, and zotarolimus-eluting coronary stents. Presented at: 20th Annual Meeting of Transcatheter Cardiovascular Therapeutics. Washington, DC, USA, 12-17 October 2008.
53. Kim JS, Jang IK, Fan C et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the Endeavor OCT Trial. JACC Cardiovasc. Interv. 2(12), 1240-1247 (2009).
54. Carter AJ, Aggarwal M, Kopia GA et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc. Res. 63(4), 617-624 (2004).
55. Hamilos M, Sarma J, Ostojic M et al. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion. Evidence for device-specific responses. Circ. Cardiovasc. Intervent. 1(3), 193-200 (2008).
56. Shin D, Seung KB, Kim PJ et al. Long-term coronary endothelial function after zotarolimus-eluting stent implantation. A 9 month comparison between zotarolimus-eluting and sirolimus-eluting stents. Int. Heart J. 49(6), 639-652 (2008).
57. Kim JW, Seo HS, Park JH et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus-versus a sirolimus-eluting stent. Differential recovery of coronary endothelial function. J. Am. Coll. Cardiol. 53(18), 1653-1659 (2009).
58. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48(12), 2584-2591 (2006).
59. Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS. Identifying the 'optimal' duration of dual antiplatelet therapy after drug-eluting stent revascularization. J. Am. Coll. Cardiol. Intv. 2(12), 1279-1285 (2009).
60. King SB III, Smith SC Jr, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO. Focused update of the ACC/AHA/SCAI 2005 guideline update for Percutaneous Coronary Intervention. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 117(2), 261-295 (2008).
61. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356(10), 989-997 (2007).
62. Mehta S, Yusuf S, Peters R et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527-533 (2001).
63. Steinhubl SR, Berger PB, Mann JT et al. for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411-2420 (2002).
64. Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297(2), 159-168 (2007).
65. Brar SS, Kim J, Brar SK et al. Long-term outcomes by clopidogrel duration and stent type on a diabetic population with de novo coronary artery lesions. J. Am. Coll. Cardiol. 51(23), 2220-2227 (2008).
66. Gwon HC. Three month duration of dual antiplatelet therapy is safe after implantation of zotarolimus-eluting stents in relatively low-risk patients with coronary artery disease: findings from the DATE registry. Presented at: The Official Congress of the European Association of Percutaneous Cardiovascular Interventions. Barcelona, Spain, 19-22 May 2009.
67. Kim JW, Kang WC, Kim KS et al. Outcome of non-cardiac surgical procedure and brief interruption of dual anti-platelet agents within 12 months following Endeavor (zotarolimus-eluting stent) stent implantation (SENS): a multicenter study. J. Am. Coll. Cardiol. 53(Suppl.), A16 (2009).